DOW JONES NEWSWIRES
Map Pharmaceuticals Inc. (MAPP) reported positive study data
related to its investigational drug Levadex, an inhaled treatment
for migraines.
Analysis showed that Levadex--the inhaled version of a drug used
for decades in emergency rooms and doctors' offices through an
intravenous line--was "effective" in treating a migraine attack
with moderate or severe pain when given as soon as the initial
migraine onset and as late as eight hours after the start of the
migraine, MAP said.
Another analysis also showed Levadex was "both effective and
well-tolerated" in migraine patients with asthma.
Earlier this year, Map said the U.S. Food and Drug
Administration wouldn't require a second efficacy trial for
Levadex, which last year met all four of its primary endpoints in
the efficacy portion of its late-stage trial.
In May, Map reported a wider first-quarter loss than a year
earlier as it saw no collaboration revenue. The company's products
are still in development.
Shares closed at $12.71 on Tuesday and was inactive premarket.
The stock has risen 15% in the past year.
-By Nathan Becker, Dow Jones Newswires; 212-416-2855;
nathan.becker@dowjones.com